Nuances of gender affirming therapy for transgender women with spinal cord injury.

IF 1.8 4区医学 Q3 CLINICAL NEUROLOGY

Journal of Spinal Cord Medicine Pub Date : 2024-09-03 DOI:10.1080/10790268.2024.2396644

Deanna Claus, Darryl Etter, Stephanie Cowherd Ryder

引用次数: 0

Abstract

Case description: 56-year-old transgender woman with new spinal cord injury (SCI) on gender affirming hormonal therapy (GAHT) with estrogen and spironolactone.

Findings: After her injury, estrogen and spironolactone were discontinued, for blood clots and hypotension, respectively. Alternative options were explored.

Clinical relevance: Little is known about GAHT in SCI for transgender women. Shared decision making should be used to navigate risks, benefits, and alternative options.

查看原文本刊更多论文

为脊髓损伤的变性女性提供性别肯定疗法的细微差别。

病例描述56 岁的变性女性，脊髓新损伤（SCI），接受雌激素和螺内酯的性别肯定激素疗法（GAHT）：受伤后，雌激素和螺内酯分别因血栓和低血压而停用。临床相关性：人们对变性女性在 SCI 中使用 GAHT 的情况知之甚少。应通过共同决策来了解风险、益处和替代方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Spinal Cord Medicine 医学-临床神经学

CiteScore

4.20

自引率

5.90%

发文量

101

审稿时长

6-12 weeks

期刊介绍： For more than three decades, The Journal of Spinal Cord Medicine has reflected the evolution of the field of spinal cord medicine. From its inception as a newsletter for physicians striving to provide the best of care, JSCM has matured into an international journal that serves professionals from all disciplines—medicine, nursing, therapy, engineering, psychology and social work.